Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
about
Epilepsy management: newer agents, unmet needs, and future treatment strategies.Anticonvulsant and Toxicological Evaluation of Parafluorinated/Chlorinated Derivatives of 3-Hydroxy-3-ethyl-3-phenylpropionamide.Transcranial Alternating Current Stimulation: A Potential Risk for Genetic Generalized Epilepsy Patients (Study Case).
P2860
Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
@en
type
label
Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
@en
prefLabel
Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
@en
P2860
P356
P1433
P1476
Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
@en
P2093
Donald F Weaver
P2860
P356
10.1111/EPI.12185
P478
54 Suppl 2
P577
2013-05-01T00:00:00Z